Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis

A phase 2 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 324 participants.

Also called NCT02022293

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 324 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02022293
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Suspended (from the registry)

Technical summary

Registry record NCT02022293. Randomized; double masking; primary purpose prevention. Start 2017-01 (actual); primary completion 2023-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis
Condition
Nasopharyngeal Carcinoma
Condition
Radiation Therapy Complication
Intervention (Drug)
Atorvastatin
Intervention (Other)
Placebo
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (class: other)

Record details

Record id
cardio:ct-nct02022293
Content hash
8357d74ebc14f17a961aaa3c35111d43d925b610f458752bb45440d8243c1ec6